TY - JOUR
T1 - BNT162b2-elicited neutralization of Delta plus, Lambda, Mu, B.1.1.519, and Theta SARS-CoV-2 variants
AU - Liu, Jianying
AU - Liu, Yang
AU - Xia, Hongjie
AU - Zou, Jing
AU - Weaver, Scott C.
AU - Swanson, Kena A.
AU - Cai, Hui
AU - Cutler, Mark
AU - Cooper, David
AU - Muik, Alexander
AU - Jansen, Kathrin U.
AU - Sahin, Ugur
AU - Xie, Xuping
AU - Dormitzer, Philip R.
AU - Shi, Pei Yong
N1 - Funding Information:
We thank the participants from Pfizer-BioNTech clinical trial C4591001, who donated the post-vaccination sera. We also thank the colleagues at Pfizer and BioNTech who developed and produced the BNT162b2 vaccine candidate. We thank Qi Yang for analysis of variant sequences. The study was supported by Pfizer and BioNTech.
Publisher Copyright:
© 2022, The Author(s).
PY - 2022/12
Y1 - 2022/12
N2 - BNT162b2-elicited human sera neutralize the currently dominant Delta SARS-CoV-2 variant. Here, we report the ability of 20 human sera, drawn 2 or 4 weeks after two doses of BNT162b2, to neutralize USA-WA1/2020 SARS-CoV-2 bearing variant spikes from Delta plus (Delta-AY.1, Delta-AY.2), Delta-∆144 (Delta with the Y144 deletion of the Alpha variant), Lambda, B.1.1.519, Theta, and Mu lineage viruses. Geometric mean plaque reduction neutralization titers against Delta-AY.1, Delta-AY.2, and Mu viruses are slightly lower than against USA-WA1/2020, but all sera neutralize the variant viruses to titers of ≥80, and neutralization titers against the Delta-∆144, Lambda, B.1.1.519 and Theta variants not significantly reduced relative to those against USA-WA1/2020. The susceptibility of Delta plus, Lambda, B.1.1.519, Theta, Mu, and other variants to neutralization by the sera indicates that antigenic change has not led to virus escape from vaccine-elicited neutralizing antibodies and supports ongoing mass immunization with BNT162b2 to control the variants and to minimize the emergence of new variants.
AB - BNT162b2-elicited human sera neutralize the currently dominant Delta SARS-CoV-2 variant. Here, we report the ability of 20 human sera, drawn 2 or 4 weeks after two doses of BNT162b2, to neutralize USA-WA1/2020 SARS-CoV-2 bearing variant spikes from Delta plus (Delta-AY.1, Delta-AY.2), Delta-∆144 (Delta with the Y144 deletion of the Alpha variant), Lambda, B.1.1.519, Theta, and Mu lineage viruses. Geometric mean plaque reduction neutralization titers against Delta-AY.1, Delta-AY.2, and Mu viruses are slightly lower than against USA-WA1/2020, but all sera neutralize the variant viruses to titers of ≥80, and neutralization titers against the Delta-∆144, Lambda, B.1.1.519 and Theta variants not significantly reduced relative to those against USA-WA1/2020. The susceptibility of Delta plus, Lambda, B.1.1.519, Theta, Mu, and other variants to neutralization by the sera indicates that antigenic change has not led to virus escape from vaccine-elicited neutralizing antibodies and supports ongoing mass immunization with BNT162b2 to control the variants and to minimize the emergence of new variants.
UR - http://www.scopus.com/inward/record.url?scp=85128017555&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85128017555&partnerID=8YFLogxK
U2 - 10.1038/s41541-022-00462-4
DO - 10.1038/s41541-022-00462-4
M3 - Article
AN - SCOPUS:85128017555
SN - 2059-0105
VL - 7
JO - npj Vaccines
JF - npj Vaccines
IS - 1
M1 - 41
ER -